
EIN TOON: Joint Cover-Up Committee on Financial Crime
Graphic
Here’s what to expect at the congressional hearings on GameStop and Robinhood
Scum sucking sack of shit lawmakers will seek to make headlines, not legislation — and all the witnesses are probably RICO eligible!
Chris Matthews, MarketWatch, 16 February 2021
Executives at Robinhood, market maker Citadel Securities, hedge fund Melvin Capital, social media firm Reddit, and Keith Gill, an independent investor who found fame and riches with his early purchases of GameStop Inc. GME, -5.52% shares, will all testify at the hearing, scheduled for noon on Thursday. Here’s what to expect:
The Gamers’ Uprising Against Wall Street Has Deep Populist Roots
Wall Street may own the country, as Kansas populist leader Mary Elizabeth Lease once declared, but a new generation of “retail” stock market traders is fighting back.
Ellen Brown, SheerPost, 10 February 2021
A short squeeze frenzy driven by a new generation of gamers captured financial headlines in recent weeks, centered on a struggling strip mall video game store called GameStop. The Internet and a year off in this shut down to study up have given a younger generation of investors the tools to compete in the market. Gerald Celente calls it the “Youth Revolution.” A group of New York Young Republicans who protested in the snow on January 31 called it “Re-occupy Wall Street.” Others have called it Occupy Wall Street 2.0.
Continue reading “Article: The Gamers’ Uprising Against Wall Street Has Deep Populist Roots”
Malcolm T. Brown is a partner at Wolf Haldenstein. He graduated from University of Pennsylvania (B.A.1988) and Rutgers University School of Law (J.D. 1994). His practice areas include: Foreign Securities Litigation, U.S. Securities Litigation, Derivative Litigation, Corporate Takeover Litigation, Unfair & Deceptive Practices, Defective Products, and Civil Rights. His bar admissions are : State of New York, State of New Jersey, Commonwealth of Pennsylvania, U. S. District Courts for the Southern, Eastern and Northern Districts of New York,, District of New Jersey, Eastern District of Pennsylvania, and U.S. Court of Appeals for the Second Circuit.
U. S. Senator Sherrod Brown (D-OH) is a minority member of the US Senate Committee on Banking. He was elected to the Senate in 2007. Prior to serving in the United States Senate, Brown served as a United States Representative for the 13th District, Ohio’s Secretary of State, a member of the Ohio General Assembly, and has taught in Ohio’s public schools and at The Ohio State University. He also serves on the Senate Committee on Finance and has served on the Senate Agriculture, Nutrition, and Forestry Committee, and he served Chairman of the Subcommittee on Jobs, Rural Economic Growth and Energy Innovation.
H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.
H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company’s shares closed last Thursday at $25.38.
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 43.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)
Christine Brown
SmarterAnalyst, 29 April 2020
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BerGenBio AS (BRRGF) today and set a price target of NOK66.00. The company’s shares closed last Monday at $1.23.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 8.2% and a 41.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Bank of America Eroded U.S. Spoof Case, Laying Path for JPMorgan
Tom Schoenberg
Bloomberg, 20 February 2020
Bank of America Corp.’s lawyers came through big for their client last year when they whittled down a U.S. case over precious metals spoofing.
Justice Department prosecutors wanted to bring criminal charges, but bank lawyers asked for none and prevailed. Prosecutors named Bank of America throughout the draft settlement document but not in the final version.